A break-even model estimated that pooled osteoporosis medications require three-year costs below $1500 for economically viable periprosthetic fracture prevention.
In plain wordsIn a computer analysis, osteoporosis medications needed three-year costs below $1500 for economically viable fracture prevention after hip replacement.
- Peptide
- Abaloparatide (Tymlos)
- Outcome
- Not applicableThree-year cost threshold for economic viability
- Study
n: not reported in source
Break-even economic analysis following hip arthroplasty for femoral neck fracture- Outcome group
- Cost-effectiveness · Musculoskeletal
Measurements
- Three-year medication cost threshold
- < 1500 USD
- pooled osteoporosis agents
Source sentences
Given the current cost and incidence of PPF, overall treatment can only be economically viable for PPF prophylaxis if the 3-year costs of these agents are less than $1500.
2 context sentences(design, population, supporting numbers)
Three-year average cost of osteoporosis medication (oral bisphosphonates, estrogen hormonal therapy, intravenous (IV) bisphosphonates, denosumab, teriparatide, and abaloparatide), costs of PPF care, and PPF rates in patients who underwent hip arthroplasty for FNFs without osteoporosis treatment were…
The absolute risk reduction (ARR) related to osteoporosis treatment and sensitivity analyses were used to evaluate the cost-effectiveness of this intervention and break-even PPF rates.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).